Literature DB >> 3861106

Immunobiology of the Dunning R-3327 rat prostate adenocarcinoma sublines: plasma and tumor effusion prostaglandins.

M W Shaw, R J Ablin, P Ray, M Rubenstein, P D Guinan, C F McKiel.   

Abstract

Enhanced production of prostaglandins (PGs) by experimentally-induced and naturally occurring tumors and their effect on tumor growth and immunosurveillance have been noted. Directed toward further evaluation of the relationship between prostatic tumor growth and its milieu, i.e., microenvironment, we investigated the possible correlation between levels of PGs, tumor size, and metastatic potential. For this purpose, the levels of PGE2 and PGF2 alpha in plasma and tumor effusions of three tumor sublines of the Dunning R-3327 rat prostate adenocarcinoma were measured: R-3327H, well-differentiated, slow-growing, and poorly metastatic; R-3327G, poorly differentiated, fast-growing, and poorly metastatic; and R-3327 Mat LyLu, anaplastic, fast-growing, and highly metastatic. The level of PGF2 alpha was highly variable with no significant differences being noted between the tumor sublines. The mean values of PGF2 alpha were, however, higher, although not significantly so, in the smaller tumors within each of the sublines. The levels of PGE2 were significantly higher in Mat LyLu effusions than those from the nonmetastasizing R-3327G and H sublines. Evaluation and comparison of the relationship between tumor burden, i.e., size versus levels of PGE2 and PGF2 alpha showed no significant differences. A vasodilator and regulator of immunological responsiveness, PGE2, may function as a modulator of tumor metastases. In consonance with studies by others elevated levels of PGE2 may possibly serve as a prognostic marker for the high metastatic potential of neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3861106     DOI: 10.1111/j.1600-0897.1985.tb00312.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol Microbiol        ISSN: 8755-8920


  6 in total

1.  Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2.

Authors:  Naoko Kobayashi; R James Barnard; Susanne M Henning; David Elashoff; Srinivasa T Reddy; Pinchas Cohen; Pak Leung; Jenny Hong-Gonzalez; Stephen J Freedland; Jonathan Said; Dorina Gui; Navindra P Seeram; Laura M Popoviciu; Dilprit Bagga; David Heber; John A Glaspy; William J Aronson
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

2.  The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer.

Authors:  Anita Hryniewicz-Jankowska; Katarzyna Augoff; Aleksander F Sikorski
Journal:  Exp Biol Med (Maywood)       Date:  2019-10

3.  Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy.

Authors:  Nicholas G Zaorsky; Mark K Buyyounouski; Tianyu Li; Eric M Horwitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-30       Impact factor: 7.038

4.  Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.

Authors:  Jiazhong Jiang; Blake Lee Neubauer; Jeremy R Graff; Marcio Chedid; James E Thomas; Neal W Roehm; Shaobo Zhang; George J Eckert; Michael O Koch; John N Eble; Liang Cheng
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

5.  Induction of Fos protein expression in spinal cord neurons of tumour-bearing rats.

Authors:  S Kergozien; J G Delcros; H Jouan; J P Moulinoux
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

6.  ACSL4 promotes prostate cancer growth, invasion and hormonal resistance.

Authors:  Xinyu Wu; Fangming Deng; Yirong Li; Garrett Daniels; Xinxin Du; Qinghu Ren; Jinhua Wang; Ling Hang Wang; Yang Yang; Valerio Zhang; David Zhang; Fei Ye; Jonathan Melamed; Marie E Monaco; Peng Lee
Journal:  Oncotarget       Date:  2015-12-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.